E-mail Article

MDLinx E-mail Article

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 emails at a time.

* From Email:

* To Email:

To Email:

Email Subject Line:

Comments:

Anti-VEGF Therapy With Bevacizumab for Anterior Segment Eye Disease

Hosseini H et al. – Besides the widely accepted use of bevacizumab in cancer therapy and chorioretinal neovascularization, the initial, striking, short–term response and patients' high tolerance of local bevacizumab therapy offer encouraging results for the potential role of anti–vascular endothelial growth factor (VEGF) agents in treating anterior segment neovascular disorders. Controlled prospective trials are needed to establish the long–term safety, efficacy, and dosing guidelines for the use of anti–VEGF agents in anterior segment neovascularization. [more...]

Cornea

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Ophthalmology Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?